313 related articles for article (PubMed ID: 23021822)
1. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium.
Lin YF; Huang MC; Liu HC
J Affect Disord; 2013 May; 147(1-3):401-6. PubMed ID: 23021822
[TBL] [Abstract][Full Text] [Related]
2. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients.
Szczepankiewicz A; Rybakowski JK; Suwalska A; Skibinska M; Leszczynska-Rodziewicz A; Dmitrzak-Weglarz M; Czerski PM; Hauser J
World J Biol Psychiatry; 2006; 7(3):158-61. PubMed ID: 16861141
[TBL] [Abstract][Full Text] [Related]
3. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.
Iwahashi K; Nishizawa D; Narita S; Numajiri M; Murayama O; Yoshihara E; Onozawa Y; Nagahori K; Fukamauchi F; Ikeda K; Ishigooka J
Clin Neuropharmacol; 2014; 37(4):108-10. PubMed ID: 24992082
[TBL] [Abstract][Full Text] [Related]
4. [Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder].
Numajiri M; Aoki J; Iwahashi K; Fukamauchi F; Enomoto M; Yoshihara E; Murayama O; Nishizawa D; Ikeda K; Ishigooka J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Jun; 32(3):161-3. PubMed ID: 22834106
[TBL] [Abstract][Full Text] [Related]
5. Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.
Benedetti F; Poletti S; Radaelli D; Locatelli C; Pirovano A; Lorenzi C; Vai B; Bollettini I; Falini A; Smeraldi E; Colombo C
Psychopharmacology (Berl); 2015 Apr; 232(7):1325-36. PubMed ID: 25345732
[TBL] [Abstract][Full Text] [Related]
6. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder.
Michelon L; Meira-Lima I; Cordeiro Q; Miguita K; Breen G; Collier D; Vallada H
Neurosci Lett; 2006 Aug; 403(3):288-93. PubMed ID: 16787706
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder.
Benedetti F; Bernasconi A; Lorenzi C; Pontiggia A; Serretti A; Colombo C; Smeraldi E
Neurosci Lett; 2004 Jan; 355(1-2):37-40. PubMed ID: 14729229
[TBL] [Abstract][Full Text] [Related]
8. Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response: Association With IMPA2, INPP1, and GSK3B Genes.
Mitjans M; Arias B; Jiménez E; Goikolea JM; Sáiz PA; García-Portilla MP; Burón P; Bobes J; Vieta E; Benabarre A
J Clin Psychopharmacol; 2015 Oct; 35(5):600-4. PubMed ID: 26267417
[TBL] [Abstract][Full Text] [Related]
9. Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder.
McCarthy MJ; Nievergelt CM; Shekhtman T; Kripke DF; Welsh DK; Kelsoe JR
Genes Brain Behav; 2011 Nov; 10(8):852-61. PubMed ID: 21781277
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
11. The impact of glycogen synthase kinase 3β gene on psychotic mania in bipolar disorder patients.
Lee YJ; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1303-8. PubMed ID: 21549170
[TBL] [Abstract][Full Text] [Related]
12. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.
Benedetti F; Serretti A; Pontiggia A; Bernasconi A; Lorenzi C; Colombo C; Smeraldi E
Neurosci Lett; 2005 Mar; 376(1):51-5. PubMed ID: 15694273
[TBL] [Abstract][Full Text] [Related]
13. The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients.
Szczepankiewicz A; Skibinska M; Suwalska A; Hauser J; Rybakowski JK
Hum Psychopharmacol; 2009 Jun; 24(4):287-91. PubMed ID: 19330793
[TBL] [Abstract][Full Text] [Related]
14. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism.
Adli M; Hollinde DL; Stamm T; Wiethoff K; Tsahuridu M; Kirchheiner J; Heinz A; Bauer M
Biol Psychiatry; 2007 Dec; 62(11):1295-302. PubMed ID: 17628506
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients].
Altınbaş K; Yeşilbaş D; İnce B; Cansız A; Sılan F; Özdemir Ö; Gülöksüz S
Turk Psikiyatri Derg; 2018; 29(2):73-78. PubMed ID: 30215834
[TBL] [Abstract][Full Text] [Related]
16. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid receptor polymorphism is associated with lithium response in bipolar patients.
Szczepankiewicz A; Rybakowski JK; Suwalska A; Hauser J
Neuro Endocrinol Lett; 2011; 32(4):545-51. PubMed ID: 21876507
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
19. A haplotype of glycogen synthase kinase 3β is associated with early onset of unipolar major depression.
Saus E; Soria V; Escaramís G; Crespo JM; Valero J; Gutiérrez-Zotes A; Martorell L; Vilella E; Menchón JM; Estivill X; Gratacòs M; Urretavizcaya M
Genes Brain Behav; 2010 Oct; 9(7):799-807. PubMed ID: 20618448
[TBL] [Abstract][Full Text] [Related]
20. The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.
Rybakowski JK; Abramowicz M; Szczepankiewicz A; Michalak M; Hauser J; Czekalski S
Int J Bipolar Disord; 2013; 1():8. PubMed ID: 25505675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
